The selectivity of inhibitors of protein kinase CK2: an update
- 15 October 2008
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 415 (3) , 353-365
Abstract
CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathological conditions with special reference to neoplasia. The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers. In the present study we show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compound TBI (or TBBz; 4,5,6,7-tetrabromo-1H-benzimidazole) are potent inhibitors of several other kinases, with special reference to PIM (provirus integration site for Moloney murine leukaemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a). In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3. In an attempt to improve selectivity towards CK2 a library of 68 TBB/TBI-related compounds have been tested for their ability to discriminate between CK2, PIM1, HIPK2 and DYRK1a, ending up with seven compounds whose efficacy toward CK2 is markedly higher than that toward the second most inhibited kinase. Two of these, K64 (3,4,5,6,7-pentabromo-1H-indazole) and K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), display an overall selectivity much higher than TBB and DMAT when tested on a panel of 80 kinases and display similar efficacy as inducers of apoptosis.Keywords
This publication has 47 references indexed in Scilit:
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- Roles of HIPK1 and HIPK2 in AML1‐ and p300‐dependent transcription, hematopoiesis and blood vessel formationThe EMBO Journal, 2006
- Validation of protein kinase CK2 as oncological targetApoptosis, 2005
- Protein kinase CK2 in mammary gland tumorigenesisOncogene, 2001
- Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)FEBS Letters, 2001
- Halogenated Benzimidazoles and Benzotriazoles as Selective Inhibitors of Protein Kinases CK-I and CK-II from Saccharomyces Cerevisiae and Other SourcesBiochemical and Biophysical Research Communications, 1995
- Asymmetric Expression of Protein Kinase CK2 Subunits in Human Kidney TumorsBiochemical and Biophysical Research Communications, 1994
- Nuclear casein kinase 2 (CK‐2) activity in human normal, benign hyperplastic, and cancerous prostateThe Prostate, 1994
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Structure and Ultraviolet Absorption Spectra of Indazole, 3-Substituted Indazole and Some of Their Derivatives1Journal of the American Chemical Society, 1950